Medtronic is in the final stage of separating its Diabetes business into MiniMed: it completed MiniMed’s IPO in March while retaining roughly 90% ownership, and launched the shareholder exchange offer on September 14, 2026 to complete the split-off.
This filing is a process correction, not a strategic update. Medtronic says the exchange offer began on September 14, 2026. 〔0〕 The only change is to the guaranteed-delivery deadline: holders using that procedure must deliver the remaining tender materials by 5:00 p.m. New York time on the second NYSE trading day after execution, rather than midnight.
The business story is unchanged. This does not alter the MiniMed separation, the number of shares offered, the ownership objective, or the exchange-offer economics described when the transaction launched. It simply removes ambiguity from how late tenders are completed; the direction and existence of the transaction were already public.
Bottom line: This is housekeeping around an already-announced separation, not a new signal about Medtronic or MiniMed. It matters operationally to shareholders using guaranteed delivery, but it does not change the investment case presented by the exchange offer itself.
Read the original 8-K on SEC EDGAR ↗